Literature DB >> 7705422

The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.

K Rudolf1, W Eberlein, W Engel, H A Wieland, K D Willim, M Entzeroth, W Wienen, A G Beck-Sickinger, H N Doods.   

Abstract

The design and subsequent in vitro and in vivo biological characterisation of the first potent and selective non-peptide neuropeptide Y Y1 receptor antagonist, BIBP3226 ((R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-argininami de) is reported. BIBP3226 displaced 125I-labelled neuropeptide Y with high affinity (Ki = 7 nM) from the human neuropeptide Y Y1 receptor and proved to be highly selective. BIBP3226 displayed potent antagonistic properties both in in vitro and in vivo models and thus represents the first selective non-peptide neuropeptide Y Y1 receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7705422     DOI: 10.1016/0014-2999(94)90822-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  50 in total

1.  Neuropeptide Y changes the excitability of fine afferent units in the rat knee joint.

Authors:  S Just; B Heppelmann
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors.

Authors:  Y Dumont; R Quirion
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

3.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

4.  Effects of a selective neuropeptide Y Y(1) receptor antagonist BIBP 3226 on double peaked vasoconstrictor responses to periarterial nerve stimulation in canine splenic arteries.

Authors:  X P Yang; S Chiba
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226.

Authors:  C Mollereau; C Gouardères; Y Dumont; M Kotani; M Detheux; H Doods; M Parmentier; R Quirion; J M Zajac
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 6.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

7.  The neuropeptide Y Y5 receptor mediates the blockade of "photic-like" NMDA-induced phase shifts in the golden hamster.

Authors:  P C Yannielli; M E Harrington
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

8.  Neuropeptide Y directly inhibits neuronal activity in a subpopulation of gonadotropin-releasing hormone-1 neurons via Y1 receptors.

Authors:  Ulrike Klenke; Stephanie Constantin; Susan Wray
Journal:  Endocrinology       Date:  2010-03-29       Impact factor: 4.736

9.  Effects of the neuropeptide YY1 receptor antagonist SR 120107A on sympathetic vascular control in pigs in vivo .

Authors:  R E Malmström; J M Lundberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

10.  Neuropeptide Y and peptide YY inhibit excitatory synaptic transmission in the rat dorsal motor nucleus of the vagus.

Authors:  Kirsteen N Browning; R Alberto Travagli
Journal:  J Physiol       Date:  2003-05-02       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.